OR WAIT null SECS
July 07, 2026
Article
Catch up on Q2 hepatology headlines, including the historic FDA approval of bulevirtide for hepatitis delta, new data on bepirovirsen for HBV, and more.
July 06, 2026
Catch up on the latest in hepatology, from bulevirtide’s FDA approval for hepatitis delta to expert perspectives on new and emerging therapies in PBC, PSC, and MASLD.
July 01, 2026
A review of 22 novel drugs approved by the US Food and Drug Administration during the first half of 2026, with links to coverage from MJH Life Sciences publications.
June 30, 2026
Video
Gideon Hirschfield, FRCP, PhD, discusses phase 2b results from VISTAs, evaluating volixibat in PSC
June 23, 2026
Zobair Younossi, MD, explains how lifestyle, drugs, and EXCEL data show steatosis and fatigue improvements in MASLD.
June 22, 2026
EPL reduced hepatic steatosis vs placebo in EXCEL MASLD trial, meeting primary endpoint at 6 months by CAP FibroScan assessment.
Michal Meron, MD, discusses her recent study indicating the potential role of the TYG index in predicting liver disease among patients without diabetes with confirmed MASLD.
June 18, 2026
Podcast
Tatyana Kushner, MD, joins hosts Brown and Reau to discuss HDV testing gaps, bulevirtide approval, and the emerging delta hepatitis pipeline.
June 11, 2026
A hepatologist discusses ALP response, fibrosis risk, and treatment optimization in PBC.
June 10, 2026
associated with cardiovascular risk
